Table 2.
Adverse events associated with delta-8-THC reported by delta-8-THC users on Reddit delta-8-THC forum r/Delta8 by MedDRA Preferred Term
| MedDRA Preferred Terms | Subcategory Prevalence |
|---|---|
| Anxiety | 16.4% (95% CI: 12.8–20.6) |
| Cough | 15.5% (95% CI: 11.6–19.4) |
| Paranoia | 9.3% (95% CI: 6.3–12.2) |
| Accidental overdose | 8.7% (95% CI: 5.7–11.9) |
| Heart rate increased | 6.9% (95% CI: 4.5–9.9) |
| Panic attack | 6.9% (95% CI: 4.2–9.6) |
| Dyspnoea | 5.7% (95% CI: 3.3–8.4) |
| Headache | 5.4% (95% CI: 3.0–7.8) |
| Nausea | 5.4% (95% CI: 3.0–7.8) |
| Vomiting | 5.4% (95% CI: 3.0–7.8) |
| Dizziness | 5.1% (95% CI: 3.0–7.5) |
| Feeling abnormal | 4.8% (95% CI: 2.7–7.2) |
| Throat irritationa | 4.2% (95% CI: 2.1–6.6) |
| Pulmonary paina | 3.9% (95% CI: 2.1–6.0) |
| Chest pain | 3.6% (95% CI: 1.8–5.7) |
| Amnesia | 3.3% (95% CI: 1.5–5.4) |
| Chest discomfort | 3.0% (95% CI: 1.5–5.1) |
| Fatigue | 3.0% (95% CI: 1.2–4.8) |
| Tremor | 3.0% (95% CI: 1.2–4.8) |
| Depression | 2.7% (95% CI: 0.9–4.5) |
| Panic reaction | 2.7% (95% CI: 1.2–4.5) |
| Withdrawal syndrome | 2.7% (95% CI: 1.2–4.5) |
| Disturbance in attention | 2.4% (95% CI: 0.9–4.2) |
| Unevaluable event | 2.4% (95% CI: 0.9–4.2) |
| Abnormal dreams | 2.1% (95% CI: 0.6–3.6) |
| Insomnia | 2.1% (95% CI: 0.6–3.9) |
| Decreased appetite | 1.8% (95% CI: 0.6–3.3) |
| Hypoaesthesia | 1.8% (95% CI: 0.6–3.3) |
| Chills | 1.8% (95% CI: 0.6–3.3) |
| Depersonalisation/derealisation disorder | 1.8% (95% CI: 0.6–3.3) |
| Somnolence | 1.8% (95% CI: 0.6–3.3) |
| Dry mouth | 1.8% (95% CI: 0.6–3.3) |
| Metamorphopsiaa | 1.8% (95% CI: 0.6–3.6) |
| Dependencea | 1.5% (95% CI: 0.3–3.0) |
| Increased appetitea | 1.5% (95% CI: 0.3–3.0) |
| Diarrhoea | 1.5% (95% CI: 0.3–3.0) |
| Head discomforta | 1.5% (95% CI: 0.3–3.0) |
| Respiratory tract irritation | 1.5% (95% CI: 0.3–3.0) |
| Productive cougha | 1.5% (95% CI: 0.3–3.0) |
| Oropharyngeal pain | 1.5% (95% CI: 0.3–2.7) |
| Abdominal pain upper | 1.5% (95% CI: 0.3–2.7) |
| Abdominal discomfort | 1.5% (95% CI: 0.3–3.0) |
| Hyperhidrosis | 1.5% (95% CI: 0.3–3.0) |
| Muscle twitching | 1.5% (95% CI: 0.3–3.0) |
| Time perception altered | 1.5% (95% CI: 0.3–3.0) |
| Vision blurred | 1.2% (95% CI: 0.3–2.4) |
| Drug withdrawal syndrome | 1.2% (95% CI: 0.3–2.7) |
| Dysarthria | 1.2% (95% CI: 0.3–2.4) |
| Hallucination, visual | 1.2% (95% CI: 0.3–2.4) |
| Autoscopya | 1.2% (95% CI: 0.3–2.7) |
| Abdominal pain | 0.9% (95% CI: 0.0–2.1) |
| Hallucinations, mixed | 0.9% (95% CI: 0.0–2.1) |
| Loss of consciousness | 0.9% (95% CI: 0.0–1.8) |
| Hypertension | 0.9% (95% CI: 0.0–2.1) |
| Ocular hyperaemia | 0.9% (95% CI: 0.0–2.1) |
| Seizure | 0.9% (95% CI: 0.0–2.1) |
| Disorientation | 0.9% (95% CI: 0.0–1.8) |
| Dissociation | 0.9% (95% CI: 0.0–1.8) |
| Irritability | 0.9% (95% CI: 0.0–2.1) |
| Muscle spasms | 0.9% (95% CI: 0.0–2.1) |
| Paraesthesia | 0.9% (95% CI: 0.0–2.1) |
| Tinnitus | 0.9% (95% CI: 0.0–2.1) |
| Sedation | 0.9% (95% CI: 0.0–2.1) |
| Sneezinga | 0.9% (95% CI: 0.0–2.1) |
| Vertigo | 0.9% (95% CI: 0.0–2.1) |
| Pain | 0.6% (95% CI: 0.0–1.5) |
| Agitation | 0.6% (95% CI: 0.0–1.5) |
| Choking sensation | 0.6% (95% CI: 0.0–1.5) |
| Delusion | 0.6% (95% CI: 0.0–1.5) |
| Depressed mooda | 0.6% (95% CI: 0.0–1.5) |
| Blood pressure increased | 0.6% (95% CI: 0.0–1.5) |
| Thirst | 0.6% (95% CI: 0.0–1.5) |
| Flatulencea | 0.6% (95% CI: 0.0–1.5) |
| Hunger | 0.6% (95% CI: 0.0–1.5) |
| Nervousness | 0.6% (95% CI: 0.0–1.5) |
| Palpitations | 0.6% (95% CI: 0.0–1.5) |
| Dysphemiaa | 0.6% (95% CI: 0.0–1.5) |
| Bruxisma | 0.6% (95% CI: 0.0–1.5) |
| Ill-defined disordera | 0.6% (95% CI: 0.0–1.5) |
| Blepharospasma | 0.6% (95% CI: 0.0–1.5) |
| Food cravinga | 0.6% (95% CI: 0.0–1.5) |
| Presyncope | 0.6% (95% CI: 0.0–1.5) |
| Tachyphrenia | 0.6% (95% CI: 0.0–1.5) |
| Abnormal loss of weighta | 0.6% (95% CI: 0.0–1.5) |
| Emotional povertya | 0.6% (95% CI: 0.0–1.5) |
| Balance disorder | 0.6% (95% CI: 0.0–1.5) |
| Sensory disturbance | 0.3% (95% CI: 0.0–0.9) |
| Acnea | 0.3% (95% CI: 0.0–0.9) |
| Hypersensitivity | 0.3% (95% CI: 0.0–0.9) |
| Altered state of consciousness | 0.3% (95% CI: 0.0–0.9) |
| Ammonia increaseda | 0.3% (95% CI: 0.0–0.9) |
| Abdominal distensiona | 0.3% (95% CI: 0.0–1.2) |
| Eye irritation | 0.3% (95% CI: 0.0–0.9) |
| Tongue discomforta | 0.3% (95% CI: 0.0–0.9) |
| Cold sweat | 0.3% (95% CI: 0.0–0.9) |
| Constipation | 0.3% (95% CI: 0.0–0.9) |
| Haemoptysisa | 0.3% (95% CI: 0.0–0.9) |
| Formication | 0.3% (95% CI: 0.0–0.9) |
| Dehydration | 0.3% (95% CI: 0.0–0.9) |
| Non-24-h sleep–wake disordera | 0.3% (95% CI: 0.0–0.9) |
| Dry eyea | 0.3% (95% CI: 0.0–0.9) |
| Dry throata | 0.3% (95% CI: 0.0–0.9) |
| Asthmaa | 0.3% (95% CI: 0.0–0.9) |
| Burning sensation | 0.3% (95% CI: 0.0–0.9) |
| Eye paina | 0.3% (95% CI: 0.0–0.9) |
| Asthenopiaa | 0.3% (95% CI: 0.0–0.9) |
| Fear | 0.3% (95% CI: 0.0–0.9) |
| Feeling jittery | 0.3% (95% CI: 0.0–0.9) |
| Feeling hot | 0.3% (95% CI: 0.0–0.9) |
| Pyrexia | 0.3% (95% CI: 0.0–0.9) |
| Photopsiaa | 0.3% (95% CI: 0.0–1.2) |
| Hallucination | 0.3% (95% CI: 0.0–0.9) |
| Hangovera | 0.3% (95% CI: 0.0–0.9) |
| Hepatic encephalopathya | 0.3% (95% CI: 0.0–0.9) |
| Urticaria | 0.3% (95% CI: 0.0–0.9) |
| Psychomotor hyperactivity | 0.3% (95% CI: 0.0–0.9) |
| Salivary hypersecretiona | 0.3% (95% CI: 0.0–0.9) |
| Apathy | 0.3% (95% CI: 0.0–0.9) |
| Hepatomegalya | 0.3% (95% CI: 0.0–0.9) |
| Ageusiaa | 0.3% (95% CI: 0.0–0.9) |
| Mood swings | 0.3% (95% CI: 0.0–0.9) |
| Nasal discomforta | 0.3% (95% CI: 0.0–0.9) |
| Rhinalgiaa | 0.3% (95% CI: 0.0–0.9) |
| Neuralgiaa | 0.3% (95% CI: 0.0–1.2) |
| Night sweats | 0.3% (95% CI: 0.0–0.9) |
| Nightmarea | 0.3% (95% CI: 0.0–0.9) |
| Epistaxis | 0.3% (95% CI: 0.0–0.9) |
| Pain in extremitya | 0.3% (95% CI: 0.0–0.9) |
| Painful respirationa | 0.3% (95% CI: 0.0–0.9) |
| Illusion | 0.3% (95% CI: 0.0–0.9) |
| Post-traumatic stress disorder | 0.3% (95% CI: 0.0–0.9) |
| Eyelid ptosisa | 0.3% (95% CI: 0.0–1.2) |
| Rhinorrhoeaa | 0.3% (95% CI: 0.0–0.9) |
| Libido increaseda | 0.3% (95% CI: 0.0–0.9) |
| Shock | 0.3% (95% CI: 0.0–0.9) |
| Sinusitis | 0.3% (95% CI: 0.0–0.9) |
| Sinus paina | 0.3% (95% CI: 0.0–0.9) |
| Sleep attacksa | 0.3% (95% CI: 0.0–0.9) |
| Poor quality sleep | 0.3% (95% CI: 0.0–0.9) |
| Odynophagiaa | 0.3% (95% CI: 0.0–0.9) |
| Swollen tongue | 0.3% (95% CI: 0.0–0.9) |
| Pharyngeal swellinga | 0.3% (95% CI: 0.0–0.9) |
| Throat tightness | 0.3% (95% CI: 0.0–0.9) |
| Vascular paina | 0.3% (95% CI: 0.0–0.9) |
| Visual impairment | 0.3% (95% CI: 0.0–0.9) |
| Weight increaseda | 0.3% (95% CI: 0.0–0.9) |
| Piloerectiona | 0.3% (95% CI: 0.0–0.9) |
| Energy increaseda | 0.3% (95% CI: 0.0–0.9) |
| Thirst decreaseda | 0.3% (95% CI: 0.0–0.9) |
| Lazinessa | 0.3% (95% CI: 0.0–0.9) |
| Perihepatic discomforta | 0.3% (95% CI: 0.0–0.9) |
| Derealisationa | 0.3% (95% CI: 0.0–0.9) |
| Negative thoughts | 0.3% (95% CI: 0.0–0.9) |
| Rash | 0.3% (95% CI: 0.0–1.2) |
| Tooth deposita | 0.3% (95% CI: 0.0–0.9) |
| Neurological symptoma | 0.3% (95% CI: 0.0–0.9) |
| Photophobiaa | 0.3% (95% CI: 0.0–0.9) |
| Intra-abdominal fluid collectiona | 0.3% (95% CI: 0.0–0.9) |
| Gastrooesophageal reflux disease | 0.3% (95% CI: 0.0–1.2) |
| Paralysis | 0.3% (95% CI: 0.0–0.9) |
| Hyperacusisa | 0.3% (95% CI: 0.0–1.2) |
| Secretion dischargea | 0.3% (95% CI: 0.0–0.9) |
| Appetite disordera | 0.3% (95% CI: 0.0–0.9) |
| Sputum discoloureda | 0.3% (95% CI: 0.0–0.9) |
| Urinary retentiona | 0.3% (95% CI: 0.0–0.9) |
| Pneumonitisa | 0.3% (95% CI: 0.0–0.9) |
| Oropharyngeal discomforta | 0.3% (95% CI: 0.0–0.9) |
| Rash erythematousa | 0.3% (95% CI: 0.0–1.2) |
| Axillary paina | 0.3% (95% CI: 0.0–0.9) |
aIndicates a MedDRA preferred term that was not listed in a FAERS case
Abbreviations: FAERS Food and Drug Administration Adverse Event Reporting System, MedDRA Medical Dictionary for Regulatory Activities